Supernus Pharmaceuticals, Inc. 0LB2.L Stock
Supernus Pharmaceuticals, Inc. Price Chart
Supernus Pharmaceuticals, Inc. 0LB2.L Financial and Trading Overview
Supernus Pharmaceuticals, Inc. stock price | 32.5 USD |
Previous Close | 33.17 USD |
Open | 0 USD |
Bid | 0 USD x 0 |
Ask | 0 USD x 0 |
Day's Range | 0 - 0 USD |
52 Week Range | 0 - 41.86 USD |
Volume | 390 USD |
Avg. Volume | 169 USD |
Market Cap | 14.81M USD |
Beta (5Y Monthly) | 1.037323 |
PE Ratio (TTM) | 0.2523592 |
EPS (TTM) | 1.31 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
0LB2.L Valuation Measures
Enterprise Value | 2.1B USD |
Trailing P/E | 0.2523592 |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 0.022157164 |
Price/Book (mrq) | 1.9801743 |
Enterprise Value/Revenue | 3.146 |
Enterprise Value/EBITDA | 16.016 |
Trading Information
Supernus Pharmaceuticals, Inc. Stock Price History
Beta (5Y Monthly) | 1.037323 |
52-Week Change | 18.95% |
S&P500 52-Week Change | 20.43% |
52 Week High | 41.86 USD |
52 Week Low | 0 USD |
50-Day Moving Average | 37.21 USD |
200-Day Moving Average | 35.93 USD |
0LB2.L Share Statistics
Avg. Volume (3 month) | 169 USD |
Avg. Daily Volume (10-Days) | 198 USD |
Shares Outstanding | 52.26M |
Float | 47.88M |
Short Ratio | N/A |
% Held by Insiders | 4.93% |
% Held by Institutions | 104.51% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | N/A |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 7.78% |
Operating Margin (ttm) | 6.95% |
Gross Margin | 86.12% |
EBITDA Margin | 19.63% |
Management Effectiveness
Return on Assets (ttm) | 1.69% |
Return on Equity (ttm) | 5.97% |
Income Statement
Revenue (ttm) | 668.5M USD |
Revenue Per Share (ttm) | 12.4 USD |
Quarterly Revenue Growth (yoy) | 0.80% |
Gross Profit (ttm) | 580.02M USD |
EBITDA | 131.29M USD |
Net Income Avi to Common (ttm) | 52.04M USD |
Diluted EPS (ttm) | 1.314 |
Quarterly Earnings Growth (yoy) | -33.80% |
Balance Sheet
Total Cash (mrq) | 228.57M USD |
Total Cash Per Share (mrq) | 4.2 USD |
Total Debt (mrq) | 524.95M USD |
Total Debt/Equity (mrq) | 57.55 USD |
Current Ratio (mrq) | 1.207 |
Book Value Per Share (mrq) | 16.746 |
Cash Flow Statement
Operating Cash Flow (ttm) | 161.65M USD |
Levered Free Cash Flow (ttm) | -301933248 USD |
Profile of Supernus Pharmaceuticals, Inc.
Country | United Kingdom |
State | MD |
City | Rockville |
Address | 9715 Key West Avenue |
ZIP | 20850 |
Phone | 301 838 2500 |
Website | https://www.supernus.com |
Industry | |
Sector(s) | |
Full Time Employees | 612 |
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; and SPN-820, a product candidate in Phase II clinical trials for treating resistant depression. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.
Q&A For Supernus Pharmaceuticals, Inc. Stock
What is a current 0LB2.L stock price?
Supernus Pharmaceuticals, Inc. 0LB2.L stock price today per share is 32.5 USD.
How to purchase Supernus Pharmaceuticals, Inc. stock?
You can buy 0LB2.L shares on the LSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Supernus Pharmaceuticals, Inc.?
The stock symbol or ticker of Supernus Pharmaceuticals, Inc. is 0LB2.L.
How many shares does Supernus Pharmaceuticals, Inc. have in circulation?
The max supply of Supernus Pharmaceuticals, Inc. shares is 446.68K.
What is Supernus Pharmaceuticals, Inc. Price to Earnings Ratio (PE Ratio)?
Supernus Pharmaceuticals, Inc. PE Ratio is 0.24733257 now.
What was Supernus Pharmaceuticals, Inc. earnings per share over the trailing 12 months (TTM)?
Supernus Pharmaceuticals, Inc. EPS is 1.31 USD over the trailing 12 months.